Propentofylline’s molecular mechanism of action is the concerted inhibition of
Na+-independent adenosine transporters and cyclic nucleotide PDEs I, 11. and IV. The
drug thereby reinforces the multiple cellular actions of the endogenous modulator
adenosine and the cellular second messengers CAMP and cGMP. Preclinical and clinical
studies indicate that propentofylline has the potential to become a safe and efticacious
drug for the treatment of both VaD and AD.
REFERENCES